Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.
Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.
Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here
Mar 1, 2017
Annual report 2016 Investor Call
Feb 7, 2017
Annual General Meeting
|Minutes of General Meeting
|Notice to Convene Annual General Meeting 2017
|Registration Form with Proxy and Absentee Vote
|Articles of Association
|AGM 2017 Presentation